| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
Operating costs and expenses: | ||||||
Research and development | ||||||
6,126 | 12,259 | 2,874 | 13,292 | 2,260 | 113 | |
Patent costs | ||||||
- | - | - | 272 | 243 | 197 | |
Patent costs | ||||||
146 | 204 | 250 | - | - | - | |
General and administrative | ||||||
4,570 | 5,425 | 4,777 | 4,881 | 6,404 | 1,969 | |
Total operating costs and expenses | ||||||
10,844 | 17,889 | 7,902 | 18,446 | 8,908 | 2,281 | |
Operating loss | ||||||
-10,844 | -17,889 | -7,902 | -18,446 | -8,908 | -2,281 | |
Other income: | ||||||
Interest expense | ||||||
- | - | - | - | - | 213 | |
Other expense | ||||||
- | - | -1 | 1 | 79 | 21 | |
Interest income | ||||||
123 | 126 | 40 | 60 | 40 | 0 | |
Settlement of accounts payable | ||||||
588 | 893 | - | - | - | - | |
Total other income | ||||||
711 | 1,020 | 38 | 62 | 120 | -191 | |
Net loss | ||||||
-10,133 | -16,868 | -7,863 | -18,384 | -8,787 | -2,473 | |
Other comprehensive gain: | ||||||
Unrealized gain on debt securities | ||||||
0 | -0 | - | - | - | - | |
Comprehensive loss | ||||||
-10,132 | -16,869 | -7,863 | - | - | - | |
Net loss | ||||||
-10,133 | -16,868 | -7,863 | - | - | - | |
Deemed dividend of preferred stock | ||||||
- | -2,537 | -3,111 | - | - | - | |
Deemed dividend of Series A preferred stock | ||||||
- | - | - | 0 | - | - | |
Cumulative preferred stock dividends | ||||||
- | - | - | - | 327 | 589 | |
Accretion of discount of Series C preferred stock | ||||||
- | - | - | - | -63 | -8 | |
Net loss applicable to common stockholders | ||||||
-10,133 | -19,406 | -10,974 | -18,384 | -9,178 | -3,071 | |
Net loss per common share - basic and diluted | ||||||
-1.06 | -3.66 | -4.95 | -2.04 | -3.11 | -6.79 | |
Weighted average common shares outstanding - basic and diluted | ||||||
9,570 | 5,304 | 2,214 | 8,993 | 2,946 | 452 | |